Source comparison
HGH Fragment 176-191 vs AOD-9604 — Same Peptide?
Researchers ordering peptides for metabolic studies often hit the same confusion point: catalogs list both 'HGH Fragment 176-191' and 'AOD-9604'. Sometimes at different price points, sometimes from different suppliers, sometimes with contradictory stability da
This comparison does not assign a generated winner or score.
- Researchers ordering peptides for metabolic studies often hit the same confusion point: catalogs list both 'HGH Fragment 176-191' and 'AOD-9604'. Sometimes at different price points, sometimes from different suppliers, sometimes with contradictory stability data. The names suggest two distinct compounds. The reality is more precise: both designations refer to an identical 15-amino-acid sequence derived from the C-terminus of human growth hormone (positions 176–191), with the AOD-9604 designation emerging from a specific clinical development program conducted in the early 2000s. The molecular structure hasn't changed. The naming reflects regulatory and commercial history rather than chemical difference.
- Our team has worked with research facilities across biotech applications for over a decade. The gap between catalog nomenclature and actual compound identity causes more protocol errors than any other peptide labeling issue we've encountered. Particularly when labs assume they need both variants for comparative studies.
- Is HGH Fragment 176-191 the same molecular structure as AOD-9604?
- Yes. HGH Fragment 176-191 and AOD-9604 contain an identical amino acid sequence (Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly) spanning positions 176 through 191 of the human growth hormone molecule. The AOD-9604 designation was assigned during Phase II clinical trials conducted by Metabolic Pharmaceuticals in Australia between 2004 and 2007, while 'Fragment 176-191' remained the standard biochemical nomenclature. Both terms describe the same 1817 Da peptide fragment with lipolytic activity but without the insulin-like growth factor-1 (IGF-1) upregulation associated with full-length hGH.
- The real distinction most labs care about isn't molecular. It's provenance. Fragment 176-191 typically appears in research supplier catalogs as a synthetic peptide synthesized via solid-phase peptide synthesis (SPPS) under Good Manufacturing Practice (GMP) standards for laboratory use. AOD-9604 carries the clinical trial designation and may appear in formulations intended for therapeutic research under Investigational New Drug (IND) protocols. The amino acid chain hasn't changed. The regulatory pathway and documentation requirements have.